Admission Date:  [**2141-9-11**]              Discharge Date:   [**2141-9-14**]  Date of Birth:  [**2117-8-7**]             Sex:   F  Service: MEDICINE  Allergies: Penicillins / Percocet  Attending:[**First Name3 (LF) 30**] Chief Complaint: Right leg pain.
She took her hydralazine, aliskirien, and labetalol at 5 AM on day of admission.
She denies any recent recrational drug use including cocaine and amphetamines.
She denies headache, vision changes, double vision, chest pain, shortness of breath, abdominal pain, BRBPR, dysuria.
She was admitted after initiation of a labetalol drip and nitropaste with improvement in sbp to 180.
The patient did have a work-up for her right leg pain complaints with plain films of the right hip and MRI of the L-spine which did not reveal an explanation for her symptoms and did rule out avascular necrosis.
The patient received dilaudid for pain control and was ambulating without pain prior to discharge.
In addition, the patient completed a course of ciprofloxacin for a positive UA with negative cultures.
Initially given labetalol 10 mg IV x 1 and then started on labetalol gtt for her elevated blood pressures and titrated to 3 mg/min.
Given morphine 4 mg IV x 1 for leg pain.
Previous treatment with cytoxan, cellcept; currently on prednisone.
Initiated dialysis [**2137**].
PD catheter placement [**5-18**].
- History of vaginal bleeding [**2139**] lasting 2 months s/p DepoProvera injection requiring transfusion.
PAST SURGICAL HISTORY: - Placement of multiple catheters including dialysis.
- PD catheter placement in [**2141-5-11**].
Negative straight leg test, no pain with internal rotation, external rotation, extension, adduction or abduction.
MRI L-SPINE [**2141-9-6**]: Diffuse low-signal intensity is identified in the bone marrow of the lumbar and lower thoracic spine as described above, possibly related with anemic changes, please correlate clinically.
LAB RESULTS AT DISCHARGE: COMPLETE BLOOD COUNT WBC RBC Hgb Hct MCV MCH MCHC RDW Plt Ct [**2141-9-14**] 06:15AM    4.0 2.63* 7.6* 23.1* 88 29.1 33.0 18.0* 100* RENAL & GLUCOSE Glucose UreaN Creat Na K Cl HCO3 AnGap [**2141-9-14**] 06:15AM    100 44* 8.1* 137 4.8 109* 17* 16 CHEMISTRY TotProt Albumin Globuln Calcium Phos Mg UricAcd Iron [**2141-9-14**] 06:15AM          6.8*  5.4*    1.6 CALCIUM freeCa [**2141-9-14**] 11:30AM    0.94*   Brief Hospital Course: ICU course: EKG showed no change from prior, and CXR showed a suggestion of RLL/R diaphragm haziness.
IV labetalol was started, and SBPS dropped from 200s to 130s-160s.
The renal team was consulted, and recommended no change to home medication regimen.
The patient was found to by hypocalcemic, and was started on calcium replacement therapy.
When stable, patient succesfully switched to PO meds and transferred to the floor.
She was maintained on her home oral medication regimen.
At night, she became more hypertensive, with SBP to the 170s-180s, which was controlled with both IV hydralazine and PO nifedipine.
PO nifedipine was most successful at bringing her SBP back to her baseline.
Throughout her hospitalization, the patient had no symptoms/signs of hypertensive emergency, including no seizures, no acute worsening of renal function, no headache, nausea, visual and mental status disturbances, chest pain, abdominal pain, or urinary symptoms.
Her pain when she was symptomatic was controlled well with PO dilaudid.
Her calcium was low during admission, and supplemental calcium was given in addition to starting Calcitriol.
She was not dialyzed through her PD catheter secondary to discomfort, but may reinitiate PD as an outpatient.
The patient is not on Epopoeitin as an outpatient, likely due to her malignant hypertension.
Prior SVC thrombus: The patient has a reported history of prior thrombus related to catheter placement in [**2139**], and was maintained on warfarin with INR goal 2.5 to 3.0. .
The patient's home prednisone regimen was continued.
Medications on Admission: - Prednisone 5 mg Daily - Coumadin 2 mg at bedtime - Nifedipine 60 mg Sustained Release Daily - Hydralazine 50 mg every 8 hours - Clonidine 0.3 mg/24 hr Patch Weekly every Wednesday - Ergocalciferol (Vitamin D2) 50,000 unit WEEKLY - Aliskiren 150 mg Twice daily - Docusate Sodium 100 mg 2 times a day - Labetalol 900 mg three times a day - Lactulose 15-30 ml once a day: goal is [**1-11**] soft bowel movements per day  Discharge Medications: 1.
Prednisone 5 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).
Clonidine 0.3 mg/24 hr Patch Weekly Sig: One (1) Patch Weekly Transdermal QWED (every Wednesday).
Calcium Carbonate 500 mg Tablet, Chewable Sig: One (1) Tablet, Chewable PO QID (4 times a day).
Lactulose 10 gram/15 mL Syrup Sig: Thirty (30) ML PO TID (3 times a day).
Calcitriol 0.5 mcg Capsule Sig: Two (2) Capsule PO DAILY (Daily).
Hydromorphone 2 mg Tablet Sig: One (1) Tablet PO Q6H (every 6 hours) as needed for Pain.
Labetalol 300 mg Tablet Sig: Three (3) Tablet PO TID (3 times a day).
Nifedipine 60 mg Tablet Sustained Release Sig: One (1) Tablet Sustained Release PO DAILY (Daily).
Aliskiren 150 mg Tablet Sig: One (1) Tablet PO BID (2 times a day).
Hydralazine 50 mg Tablet Sig: One (1) Tablet PO Q8H (every 8 hours).
Diphenhydramine HCl 25 mg Capsule Sig: One (1) Capsule PO Q6H (every 6 hours) as needed for itching.
Previous treatment with cytoxan, cellcept; currently on prednisone.
Initiated dialysis [**2137**].
PD catheter placement [**5-18**].
Negative Beta-2 glycoprotein antibody ([**4-/2138**], [**8-/2140**]) - HOCM: Last noted on echo [**8-17**] - Anemia - History of left eye enucleation [**2139-4-20**] for fungal infection - History of vaginal bleeding [**2139**] lasting 2 months s/p DepoProvera injection requiring transfusion.
You spent one day in the intensive care unit, where you were treated with intravenous medication to lower your blood pressure.
Please take your medications as prescribed.
- Calcitriol was added to your medications.
- You should hold Coumadin for two days and restart Saturday, [**2141-9-16**].
- You can take Dilaudid 2-4 mg every eight hours as needed for pain.
- You should continue Lactulose as per Dr.[**Name (NI) 12913**] instructions.
